Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

BACKGROUND Among the recently reported cholesterol-lowering drug trials, the JUPITER (Justification for the Use of Statins in Primary Prevention) trial is unique: it reports a substantial decrease in the risk of cardiovascular diseases among patients without coronary heart disease and with normal or low cholesterol levels. METHODS Careful review of both results and methods used in the trial and comparison with expected data. RESULTS The trial was flawed. It was discontinued (according to prespecified rules) after fewer than 2 years of follow-up, with no differences between the 2 groups on the most objective criteria. Clinical data showed a major discrepancy between significant reduction of nonfatal stroke and myocardial infarction but no effect on mortality from stroke and myocardial infarction. Cardiovascular mortality was surprisingly low compared with total mortality-between 5% and 18%-whereas the expected rate would have been close to 40%. Finally, there was a very low case-fatality rate of myocardial infarction, far from the expected number of close to 50%. The possibility that bias entered the trial is particularly concerning because of the strong commercial interest in the study. CONCLUSION The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors.

[1]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[2]  P. Ridker.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. , 2003, Circulation.

[3]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[4]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[5]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[6]  Jean-Louis Martin,et al.  Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction , 2002, Circulation.

[7]  M. Steinman,et al.  The Neurontin legacy--marketing through misinformation and manipulation. , 2009, The New England journal of medicine.

[8]  Robert J. Glynn,et al.  Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.

[9]  D. Mikhailidis,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.

[10]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[11]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[12]  P. Ridker.  The JUPITER Trial: Results, Controversies, and Implications for Prevention , 2009, Circulation. Cardiovascular quality and outcomes.

[13]  M. de Lorgeril,et al.  Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory? , 2009, World review of nutrition and dietetics.

[14]  G. Dagenais,et al.  Fluctuating inflammatory markers in patients with stable ischemic heart disease. , 2005, Archives of internal medicine.

[15]  P. Greenland,et al.  Critical lessons from the ENHANCE trial. , 2008, JAMA.

[16]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[17]  Jean-Louis Martin,et al.  Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study , 1999 .

[18]  E. Steyerberg,et al.  Rosuvastatin in patients with elevated C-reactive protein. , 2009, The New England journal of medicine.

[19]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[20]  R. Erbel,et al.  Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden , 2008, Circulation.

[21]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[22]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[23]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[24]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[25]  G. Guyatt,et al.  Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit , 2007, Annals of Internal Medicine.

[26]  A. Michałek.  [Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ]. , 2008, Kardiologia polska.

[27]  J J Heger,et al.  Sudden cardiac death. , 1998, Circulation.

[28]  Kevin L. Thomas,et al.  Systematic review of the incidence of sudden cardiac death in the United States. , 2011, Journal of the American College of Cardiology.

[29]  George A. Mensah,et al.  Sudden Cardiac Death in the United States, 1989 to 1998 , 2001, Circulation.

[30]  Winfried März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .

[31]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[32]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[33]  M. Desai,et al.  From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999–2004 National Health and Nutrition Examination Survey , 2009, Circulation. Cardiovascular quality and outcomes.

[34]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. , 1999, Lancet.

[35]  F. Boucher,et al.  Mediterranean diet and the French paradox: two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease. , 2002, Cardiovascular research.

[36]  V. Vaccarino,et al.  JUPITER: A Few Words of Caution , 2009, Circulation. Cardiovascular quality and outcomes.

[37]  R. Gibbons.  Rosuvastatin in patients with elevated C-reactive protein. , 2009, The New England journal of medicine.

[38]  Harlan M Krumholz,et al.  Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. , 2008, JAMA.

[39]  M. de Lorgeril,et al.  Cholesterol lowering and mortality: time for a new paradigm? , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[40]  M. Hlatky.  Expanding the orbit of primary prevention--moving beyond JUPITER. , 2008, The New England journal of medicine.

[41]  G. Guyatt,et al.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.

[42]  R. Virmani,et al.  Sudden cardiac death. , 1987, Human pathology.

[43]  R. Collins,et al.  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) , 2009 .

[44]  N. Donner‐Banzhoff,et al.  Statins and primary prevention of cardiovascular events , 2008, BMJ : British Medical Journal.

[45]  P. Ridker,et al.  Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. , 2010, Journal of the American College of Cardiology.

[46]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[47]  M. Mitka.  Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct. , 2008, JAMA.

[48]  R. Collins,et al.  Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. , 2007, American heart journal.

[49]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[50]  S. Nissen.  The Jupiter trial: Key findings, controversies, and implications , 2009, Current cardiology reports.

[51]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.

[52]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.